Unknown Cancer NIHR-supported project Digestion, Kidneys & Other Organs
ASpiRE: A proof-of-mechanism and proof-of-concept clinical trial evaluating the safety, tolerability, biological and anti-tumour activity of Apalutamide with dual CXCR1 and CXCR2 blockade by SX-682 for men suffering from metastatic castration-resistant prostate cancer (mCRPC)
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Simon Pacey (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
ACE: Proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mCRPC)
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus a Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC)
CRUKD/17/007 POLERISE A phase Ib/IIa trial to combine the CSF1 receptor inhibitor PLX3397 with the new generation AR antagonist enzalutamide in metastatic castration resistant prostate cancer
ACTION: Phase I/II Trial of Abiraterone Acetate in Combination with Tildrakizumab (anti-IL23 targeting monoclonal antibody) in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase1, first-in-human study of the safety, pharmacokinetics, and preliminary efficacy of AMX-500 in participants with metastatic castration-resistant prostate cancer (mCRPC)
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know